Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Phase II study of GS-7340 meets 24-week primary objective

Nov. 5, 2012

British and French group presents novel vaccines for AIDS

Nov. 5, 2012

Shionogi and ViiV Healthcare form new integrase inhibitor agreement

Oct. 30, 2012

CytoDyn acquires antibody inhibiting HIV entry

Oct. 18, 2012

City of Hope discloses new siRNA systems for HIV

Oct. 11, 2012

Shionogi-ViiV Healthcare completes initial registration package for dolutegravir

Oct. 5, 2012

U.S. government awards GeoVax a grant for its HIV vaccine program

Oct. 3, 2012

First-in-human study of Opal-HIV-Gag(c) terminated

Sep. 25, 2012

Scripps Research Institute receives grant for HIV research

Sep. 21, 2012

Bionor Pharma presents phase II results for HIV vaccine

Sep. 20, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...